VILAMOURA, Portugal — At the ESCRS winter meeting, Paolo Nucci, MD, addressed the hot topic of myopia control. Myopia progression can be slowed down, he said, but consensus on treatment options and optimization has not been reached.
“Atropine at low concentration is available, but scientists are debating if 0.01%, 0.02% or 0.05% is the best option, and this creates confusion,” he said. “Defocus lenses have been studied for almost 20 years. Now we have different types of defocus lenses, but competition among the industries also creates confusion.”
He also expressed